BCMA-targeted CAR-T therapy, which has shown promise in treating multiple myeloma, is also gaining attention for MG, as reported by a case where bispecific BCMA/CD19 CAR-T cells induced remission in a 64-year-old patient (Zhang et al., 2024). Here, TNFRSF17 is linked to plasma cell myeloma.